Despite the growing attractiveness of DUBs as therapeutic targets and the advancements in the field of DUB discovery and target identification, only a handful of DUB inhibitors, such as VLX1570, have advanced through clinical trials for cancer therapy. The gene discussed is ZUP1; the disease is cancer.